Replies to post #19954 on RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I don't think PIPEs are an option until share-price is a dollar higher, so whatever their motive, they never got the leverage. I certainly don't think they tried to arrange things for an August announcement, but since that's the way things turned out, my guess is that they want to postpone RD1 until after labor day. If that produces a more substantial bounce then they have the PIPE option, but I don't think the market is going to be convinced by the science by itself. There has to be the kind of partnership buzz that Neuro referred to to produce a share-price increase, and with a partnership in hand, it isn't obvious why they would also do a PIPE. So I don't foresee a PIPE.

Of course, if the RD-1 results were to undercut efficacy and/or analgesia preservation, then a PIPE would likely be futile too, since the terms would be so bad.

I think cor has to get a partnership deal. It is the only thing that will restore credibility to this company. Cor has established efficacy for 2 multimillion dollar indications, there are no major safety issues with the low-impacts, and yet the stock is still below a dollar. More science isn't going to change how the market views cor.

[neuroinv]

I am absolutely certain that the financial incentives for RD2 had nothing to do with preparing a package for a PIPE. Earlier completion did allow them to at least sow the seeds for partnership discussions once summer has ended. But it would be a mistake to disregard how seriously Stoll takes keeping his promises, and his awareness that Cortex shareholders have learned to be skeptical based on past unpleasant surprises--and not wanting to again leave them feeling that Cortex had not delivered. To the degree to which timeliness was under his control (and financial incentives are the only lever they had), he was going to try to meet the end of July timeframe he'd set. With financial incentives not feasible for RD1 due to the academic setting, he didn't have the same control there.

NeuroInvestment